Emergent Biosolutions EBS Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Emergent Biosolutions in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Emergent Biosolutions's other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Emergent Biosolutions's other accrued liabilities?
- Emergent Biosolutions (EBS) reported other accrued liabilities of $8M in Q1 2026.
- How has Emergent Biosolutions's other accrued liabilities changed year-over-year?
- Emergent Biosolutions's other accrued liabilities decreased by 27.9% year-over-year, from $11.1M to $8M.
- What is the long-term trend for Emergent Biosolutions's other accrued liabilities?
- Over 5 years (2020 to 2025), Emergent Biosolutions's other accrued liabilities has grown at a -33.5% compound annual growth rate (CAGR), from $83.1M to $10.8M.
- What does other accrued liabilities mean?
- This captures miscellaneous short-term obligations that do not fit into standard categories like accounts payable or accrued compensation. It often includes items such as customer deposits, short-term tax provisions, or other minor contractual liabilities. It provides insight into the breadth of the company's short-term financial commitments.